Compare Lowe`s Companies Inc (LOW) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Neurocrine Biosciences Inc — how do they compare? Lowe`s Companies Inc trades at $186 (market cap $105.96B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Lowe`s Companies Inc is far larger — about 7.4× Neurocrine Biosciences Inc's market cap, and Lowe`s Companies Inc pays a 2.65% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lowe`s Companies Inc for 98 Days and Neurocrine Biosciences Inc for 23 Days on average.
| LOW | NBIX | |
|---|---|---|
Market Cap | $105.96B | $14.36B |
Volume | 4,039,547 | 1,237,180 |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $185.50 |
52-Week Low | $179.50 | $123.10 |
Typical Hold Time | 98 Days | 23 Days |
Enterprise Value | $144.81B | $14.37B |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $188.85, up 4.03% with recent earnings beats but faces a bearish technical outlook. The stock shows solid fundamentals with a P/E of 15.96 and net margin of 7.35%, though revenue declined to $83.67B in 2025. Recent news highlights drone delivery innovation with DoorDash and Alphabet, while the home improvement sector contends with a slowing housing market.
Wall Street maintains a bullish consensus with a $244.09 price target (60.8% buy ratings), but risks include high debt levels and economic sensitivity. The stock offers value with dividend payments, yet investors must weigh competitive pressures and macroeconomic headwinds against its innovation efforts and market position.
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
